The Emerging Role of HRD Testing and the Progress of PARP Inhibitors in Ovarian Cancer - European Medical Journal

The Emerging Role of HRD Testing and the Progress of PARP Inhibitors in Ovarian Cancer

Oncology

The EMJ Podcast | Bonus Episode

In this EMJ podcast episode, David O’Malley, Director of Gynecologic Oncology, Ohio State University, and the James Comprehensive Cancer Center, Columbus, Ohio, USA, and Christina Fotopoulou, Consultant Gynaecological Oncologist, Queen Charlotte’s & Chelsea Hospital, London, UK, discuss the role of homologous recombination deficiency (HRD) testing, and the progress of poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer.

Spotify | Apple | Amazon MusicDownload MP3 (mp3, 41:05 mins)

The publication of this podcast was funded by a medical educational grant from AstraZeneca with the purpose of enhancing the fundamental understanding of oncology specialists of the role and value of homologous recombination deficiency (HRD) testing and progress in the use of poly(ADP-ribose) polymerase (PARP) inhibitors.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now